- Home
- HLP vs CRDL Comparison
HLP vs CRDL Comparison
Compare HLP & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLP
- CRDL
- Stock Information
- Founded
- HLP 2021
- CRDL 2017
- Country
- HLP China
- CRDL Canada
- Employees
- HLP N/A
- CRDL N/A
- Industry
- HLP Industrial Machinery/Components
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HLP Industrials
- CRDL Health Care
- Exchange
- HLP Nasdaq
- CRDL Nasdaq
- Market Cap
- HLP 96.2M
- CRDL 102.0M
- IPO Year
- HLP 2023
- CRDL N/A
- Fundamental
- Price
- HLP $1.28
- CRDL $0.96
- Analyst Decision
- HLP
- CRDL Strong Buy
- Analyst Count
- HLP 0
- CRDL 3
- Target Price
- HLP N/A
- CRDL $9.00
- AVG Volume (30 Days)
- HLP 20.0K
- CRDL 243.4K
- Earning Date
- HLP 04-08-2025
- CRDL 05-13-2025
- Dividend Yield
- HLP N/A
- CRDL N/A
- EPS Growth
- HLP N/A
- CRDL N/A
- EPS
- HLP N/A
- CRDL N/A
- Revenue
- HLP $14,045,084.00
- CRDL N/A
- Revenue This Year
- HLP N/A
- CRDL N/A
- Revenue Next Year
- HLP N/A
- CRDL N/A
- P/E Ratio
- HLP N/A
- CRDL N/A
- Revenue Growth
- HLP N/A
- CRDL N/A
- 52 Week Low
- HLP $1.00
- CRDL $0.91
- 52 Week High
- HLP $2.25
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- HLP 42.70
- CRDL 34.61
- Support Level
- HLP $1.28
- CRDL $1.10
- Resistance Level
- HLP $1.40
- CRDL $1.18
- Average True Range (ATR)
- HLP 0.04
- CRDL 0.09
- MACD
- HLP -0.01
- CRDL -0.01
- Stochastic Oscillator
- HLP 2.00
- CRDL 14.78
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll formed steel profile manufacturer in China. It customizes and manufactures cold roll formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture and transportation.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.